According to AVEO Oncology 's latest financial reports the company's current earnings (TTM) are -$29.04 M. In 2021 the company made an earning of -$53.35 M a decrease over its 2020 earnings that were of -$35.59 M.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2022 (TTM) | -$29.04 M | -45.56% |
2021 | -$53.35 M | 49.9% |
2020 | -$35.59 M | -479.04% |
2019 | $9.38 M | -276.17% |
2018 | -$5.33 M | -91.79% |
2017 | -$64.93 M | 142.38% |
2016 | -$26.79 M | 78.51% |
2015 | -$15.01 M | -71.55% |
2014 | -$52.74 M | -50.72% |
2013 | -$0.11 B | -4.88% |
2012 | -$0.12 B | -426.29% |
2011 | $34.48 M | -159.85% |
2010 | -$57.63 M | 35.33% |
2009 | -$42.59 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Eli Lilly LLY | $6.55 B | -22,671.71% | ๐บ๐ธ USA |
Amgen AMGN | $7.85 B | -27,149.83% | ๐บ๐ธ USA |
Biogen BIIB | $1.29 B | -4,565.72% | ๐บ๐ธ USA |
Regeneron Pharmaceuticals REGN | $4.19 B | -14,560.90% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $8.44 B | -29,164.36% | ๐บ๐ธ USA |
Merrimack Pharmaceuticals MACK | -$2.18 M | -92.51% | ๐บ๐ธ USA |